AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11920167 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 64
Study 9228508 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard liquid diet (Biosorb Sonde)
Number of subjects: 10
Study 9228508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre containing diet (Biosorb Plus Sonde)
Number of subjects: 10
Study 9228508 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate modified, fructose containing 'diabetes' diet (Fresubin Diabetes)
Number of subjects: 10
Study 8144244 — intervention group
Group type: EXPERIMENTAL
Intervention: Kloroperka
Number of subjects: 0
Study 8144244 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 0
Study 8144244 — intervention group
Group type: COMPARATOR
Intervention: ProcoSol
Number of subjects: 0
Study 3539737 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m 1099 (alpha-glucosidase inhibitor)
Number of subjects: 0
Study 3539737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30100279 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland Mobilization
Number of subjects: 30
Study 30100279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization with Movement (MWM)
Number of subjects: 30
Study 26183139 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerex
Number of subjects: 60
Study 26183139 — intervention group
Group type: COMPARATOR
Intervention: PPS
Number of subjects: 60
Study 24807721 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC/AIDSVax vaccine
Number of subjects: 0
Study 24807721 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 and V2 monoclonal antibodies isolated from RV144 vaccinees
Number of subjects: 0
Study 24807721 — intervention group
Group type: EXPERIMENTAL
Intervention: V2 monoclonal antibody CH58
Number of subjects: 0
Study 24807721 — intervention group
Group type: COMPARATOR
Intervention: Low IgA Env antibody levels
Number of subjects: 0
Study 22928374 — intervention group
Group type: EXPERIMENTAL
Intervention: Home bleaching with 10% carbamide peroxide (CP) for 4 hours a day, over the course of 3 weeks
Number of subjects: 40
Study 22928374 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) with three 10-minute applications at each session and no light source
Number of subjects: 40
Study 22928374 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) with quartz‐tungsten‐halogen light irradiation
Number of subjects: 40
Study 22928374 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) with LED/laser light irradiation
Number of subjects: 40
Study 20950416 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 1608
Study 20950416 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (RT)
Number of subjects: 1608
Study 17632400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 43
Study 15755303 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback and personal book
Number of subjects: 130
Study 15755303 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal book only
Number of subjects: 130
Study 15755303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 12194122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaseline)
Number of subjects: 102
Study 12194122 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 102
Study 12194122 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% prilocaine‐5% lidocaine (EMLA)
Number of subjects: 102
Study 12194122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% glyceryl trinitrate ointment (GTN)
Number of subjects: 102
Study 9472426 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 40
Study 9472426 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital 100 mg
Number of subjects: 40
Study 9472426 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (natural sleep)
Number of subjects: 40
Study 8585581 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin containing folic acid
Number of subjects: 866
Study 8585581 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin containing folic acid (after controlling for confounding factors)
Number of subjects: 866
Study 8585581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal containing folic acid
Number of subjects: 866
Study 8585581 — intervention group
Group type: COMPARATOR
Intervention: No multivitamin use
Number of subjects: 866
Study 2744186 — intervention group
Group type: EXPERIMENTAL
Intervention: Anandron (100 mg twice a day)
Number of subjects: 18
Study 2744186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2744186 — intervention group
Group type: EXPERIMENTAL
Intervention: Anandron
Number of subjects: 18
Study 1086117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre‐optic endoscopy
Number of subjects: 53
Study 1086117 — intervention group
Group type: COMPARATOR
Intervention: Double‐contrast radiology
Number of subjects: 53
Study 1086117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre‐optic endoscopy and double‐contrast radiology
Number of subjects: 53
Study 31288877 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified barbed pharyngoplasty
Number of subjects: 34
Study 31288877 — intervention group
Group type: COMPARATOR
Intervention: Barbed pharyngoplasty
Number of subjects: 34
Study 28594587 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY)
Number of subjects: 6108
Study 28594587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6108
Study 26908303 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐methadone 40 mg PO twice daily for 12 days
Number of subjects: 10
Study 26908303 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐methadone
Number of subjects: 10
Study 26908303 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐methadone 40 mg PO Q 12 hours
Number of subjects: 10
Study 24945621 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 20
Study 24945621 — intervention group
Group type: COMPARATOR
Intervention: 500-Hz tonic stimulation
Number of subjects: 20
Study 24945621 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 20
Study 22574588 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV combined with SY
Number of subjects: 164
Study 22574588 — intervention group
Group type: COMPARATOR
Intervention: ETV
Number of subjects: 164
Study 20005692 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuser
Number of subjects: 516
Study 20005692 — intervention group
Group type: COMPARATOR
Intervention: Substance use disorder
Number of subjects: 516
Study 17082463 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (PB) 500 mg/kg/day, intermittent regimen (7 days on/7 days off) for 13 weeks
Number of subjects: 107
Study 17082463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 17082463 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (PB)
Number of subjects: 107
Study 16120154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% progesterone cream
Number of subjects: 40
Study 16120154 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study 12486461 — intervention group
Group type: EXPERIMENTAL
Intervention: Japan's articles in orthopedics
Number of subjects: 878
Study 12486461 — intervention group
Group type: COMPARATOR
Intervention: Total articles published in orthopedics journals
Number of subjects: 878
Study 12486461 — intervention group
Group type: EXPERIMENTAL
Intervention: Japan's contribution to orthopedics research
Number of subjects: 878
Study 12486461 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of clinical research studies in Japan
Number of subjects: 878
Study 10584982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg) at a concentration of 10 mg/mL
Number of subjects: 20
Study 10584982 — intervention group
Group type: COMPARATOR
Intervention: Control group (lymphocytes of pregnant women not at risk of abortion)
Number of subjects: 20
Study 8543703 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet alone
Number of subjects: 1137
Study 8543703 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet with computer-generated personalized feedback
Number of subjects: 1137
Study 8543703 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet, personalized feedback, and outreach telephone counseling
Number of subjects: 1137
Study 8543703 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 1137
Study 8543703 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 1137
Study 1516608 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol base in aerosol
Number of subjects: 12
Study 1516608 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of powder
Number of subjects: 12
Study 1516608 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (both forms)
Number of subjects: 12
Study 1516608 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol powder
Number of subjects: 12
Study 1516608 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI
Number of subjects: 12
Study 6509946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gold
Number of subjects: 116
Study 6509946 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable gold
Number of subjects: 116
Study 6509946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 30730481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training
Number of subjects: 402
Study 30730481 — intervention group
Group type: COMPARATOR
Intervention: Arthritis Education
Number of subjects: 402
Study 30730481 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 402
Study 29095431 — intervention group
Group type: EXPERIMENTAL
Intervention: Double phototherapy (n=41)
Number of subjects: 83
Study 29095431 — intervention group
Group type: COMPARATOR
Intervention: Single phototherapy (n=42)
Number of subjects: 83
Study 26704141 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua multifocal
Number of subjects: 35
Study 26704141 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision 2 for Presbyopia
Number of subjects: 35
Study 26704141 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue OASYS for Presbyopia
Number of subjects: 35
Study 26704141 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity multifocal
Number of subjects: 35
Study 26704141 — intervention group
Group type: COMPARATOR
Intervention: Monovision with Biofinity
Number of subjects: 35
Study 26704141 — intervention group
Group type: EXPERIMENTAL
Intervention: All lenses
Number of subjects: 35
Study 28033526 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC-1) with TPF ± cetuximab
Number of subjects: 52
Study 23485078 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone monotherapy (1‐2 mg/kg/d; maximal total dose, ≤60 mg)
Number of subjects: 60
Study 23485078 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone + fluvastatin (5 mg/d if aged <5 years; 10 mg/d if aged ≥5 years)
Number of subjects: 60
Study 23485078 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children without evidence of renal, hepatobiliary, cardiovascular, or hematologic disease)
Number of subjects: 60
Study 21075564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abstinent patients
Number of subjects: 43
Study 21075564 — intervention group
Group type: COMPARATOR
Intervention: Non‐using controls
Number of subjects: 43
Study 18800069 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg per day)
Number of subjects: 53
Study 18800069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 17470689 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents (AAs) including bevacizumab, SU11248, and BAY‐43‐9006 combined with radiation therapy
Number of subjects: 0
Study 17470689 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 15055891 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 7.5 mg combined with S(+) ketamine 0.1 mg kg(‐1)
Number of subjects: 40
Study 15055891 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 10 mg
Number of subjects: 40
Study 11738125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Tai Chi (48 weeks, twice per week)
Number of subjects: 0
Study 11738125 — intervention group
Group type: COMPARATOR
Intervention: Wellness education program
Number of subjects: 0
Study 11738125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Tai Chi
Number of subjects: 0
Study 9625322 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Number of subjects: 66
Study 9625322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 7602025 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, > or = 25 mg/day for at least 5 days after MI
Number of subjects: 118
Study 7602025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta-blocker therapy)
Number of subjects: 118
Study 2113094 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 23
Study 2113094 — intervention group
Group type: COMPARATOR
Intervention: HATG
Number of subjects: 23
Study 371421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and short-term interpersonal psychotherapy
Number of subjects: 0
Study 371421 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone (tricyclic antidepressants)
Number of subjects: 0
Study 371421 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy alone (various psychotherapies)
Number of subjects: 0
Study 371421 — intervention group
Group type: COMPARATOR
Intervention: Nonscheduled supportive psychotherapy
Number of subjects: 0
Study 31520309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous Ascorbate (FA)
Number of subjects: 125
Study 31520309 — intervention group
Group type: COMPARATOR
Intervention: Iron Polymaltose Complex (IPC)
Number of subjects: 125
Study 29375198 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligomeric proanthocyanidin nutritional supplement
Number of subjects: 20
Study 29375198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 25881322 — intervention group
Group type: COMPARATOR
Intervention: Locomotor treadmill training (LTT) alone
Number of subjects: 48
Study 25881322 — intervention group
Group type: EXPERIMENTAL
Intervention: LTT combined with Tizanidine (TizLTT)
Number of subjects: 48
Study 25881322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LTT and TizLTT
Number of subjects: 48
Study 25881322 — intervention group
Group type: EXPERIMENTAL
Intervention: TizLTT
Number of subjects: 48
Study 22778053 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home-based training program
Number of subjects: 0
Study 22778053 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20739195 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg INT131 besylate
Number of subjects: 0
Study 20739195 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg INT131 besylate
Number of subjects: 0
Study 20739195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19577749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mug)
Number of subjects: 40
Study 19577749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16752617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways implemented through the Medical Patient Management program in the test group (n = 50)
Number of subjects: 91
Study 16752617 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 41)
Number of subjects: 91
Study 14711717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU daily)
Number of subjects: 1193
Study 14711717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study 11699480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual acid-etched implants
Number of subjects: 97
Study 11699480 — intervention group
Group type: COMPARATOR
Intervention: Machined-surfaced implants
Number of subjects: 97
Study 11699480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual acid-etched implants in poor quality or soft bone
Number of subjects: 97
Study 11699480 — intervention group
Group type: COMPARATOR
Intervention: Machined-surfaced implants in poor quality or soft bone
Number of subjects: 97
Study 9441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese rifapentine
Number of subjects: 287
Study 9441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Second batch of Chinese rifapentine
Number of subjects: 287
Study 9441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of last two batches of Chinese rifapentine (750 mg to 900 mg)
Number of subjects: 287
Study 9441094 — intervention group
Group type: EXPERIMENTAL
Intervention: All batches of rifapentine
Number of subjects: 287
Study 7961057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (6.75 micrograms)
Number of subjects: 48
Study 7961057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (6 micrograms)
Number of subjects: 48
Study 7961057 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 48
Study 7961057 — intervention group
Group type: COMPARATOR
Intervention: Regular breakfast
Number of subjects: 48
Study 7961057 — intervention group
Group type: COMPARATOR
Intervention: Opulent meal
Number of subjects: 48
Study 2239975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IV IgG) 1 g/kg administered every 30 days for 6 months
Number of subjects: 30
Study 2239975 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (1% albumin solution) administered every 30 days for 6 months
Number of subjects: 30
Study 2239975 — intervention group
Group type: COMPARATOR
Intervention: Both IV IgG and placebo groups
Number of subjects: 30
Study 79080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral electrolyte solutions containing sucrose
Number of subjects: 51
Study 79080 — intervention group
Group type: COMPARATOR
Intervention: Oral electrolyte solutions containing glucose
Number of subjects: 51
Study 31652479 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐OHPC (250 mg IM weekly)
Number of subjects: 1708
Study 30286483 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium and Vitamin E co-supplementation (250 mg/day magnesium plus 400 mg/day vitamin E)
Number of subjects: 60
Study 30286483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28753100 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 68
Study 28753100 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CM
Number of subjects: 68
Study 28753100 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + EMD
Number of subjects: 68
Study 28753100 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CM + EMD
Number of subjects: 68
Study 25547929 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive safety decision aid
Number of subjects: 708
Study 25547929 — intervention group
Group type: COMPARATOR
Intervention: Usual safety planning resources
Number of subjects: 708
Study 24138348 — intervention group
Group type: EXPERIMENTAL
Intervention: Energize program
Number of subjects: 104
Study 24138348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 21473754 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (CBT)
Number of subjects: 85
Study 21473754 — intervention group
Group type: COMPARATOR
Intervention: Discussion forum (Control)
Number of subjects: 85
Study 19126587 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions)
Number of subjects: 981
Study 19126587 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care only)
Number of subjects: 981
Study 16153646 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 404
Study 15350372 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m² intravenously over 3 hours) and Carboplatin (AUC 6) every 3 weeks
Number of subjects: 6
Study 11347795 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 mg bid)
Number of subjects: 5
Study 11347795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 11347795 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and Placebo
Number of subjects: 5
Study 9389398 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with division of short gastric vessels (SGVs) (52 patients)
Number of subjects: 102
Study 9389398 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without division of short gastric vessels (SGVs) (50 patients)
Number of subjects: 102
Study 8110432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride (200 mmol/day)
Number of subjects: 15
Study 8110432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (200 mmol/day)
Number of subjects: 15
Study 8110432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride and sodium citrate
Number of subjects: 15
Study 3816107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 1.0 g
Number of subjects: 40
Study 3816107 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride 1.3 g
Number of subjects: 40
Study 29196864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-tapping-exercise intervention (15 min of tapping a plastic ball)
Number of subjects: 30
Study 29196864 — intervention group
Group type: COMPARATOR
Intervention: Story-time (control condition)
Number of subjects: 30
Study 29196864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-tapping-exercise intervention
Number of subjects: 30
Study 27846175 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable tacker fixation (AT group)
Number of subjects: 90
Study 27846175 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable tacker fixation (NAT group)
Number of subjects: 90